Cynosure, Inc. (CYNO) - NASDAQ
  • Jul. 29, 2014, 12:47 PM
    | Jul. 29, 2014, 12:47 PM | 1 Comment
  • Feb. 12, 2014, 9:10 AM
    | Feb. 12, 2014, 9:10 AM
  • Jul. 31, 2013, 12:10 PM
    • Cynosure (CYNO +6.6%) moves up today after reporting Q2 earnings that beat Street estimates this morning.
    • Revenue rose 27% Y/Y, reflecting higher laser product sales across its distribution channels as well as an additional $5.1M in revenue from five days of sales attributable to its Palomar acquisition.
    • Operating expenses rose to $42.4M, which included $20.4M in acquisition expenses.
    • The company noted that it expects to complete its integration of the Palomar acquisition over the next several quarters, with the acquisition still on pace to be accretive in FY14.
    | Jul. 31, 2013, 12:10 PM
  • May 23, 2013, 8:23 AM

    Domino's Pizza (DPZ) +3.3% premarket on news it will replace Plains Exploration (PXP) in the S&P MidCap 400 after the close on May 30. Cynosure (CYNO), which will replace NCI Building Systems (NCS), +4.3%. NCS -5.5%.

    | May 23, 2013, 8:23 AM
  • Nov. 16, 2012, 4:08 PM

    Cynosure (CYNO +6.6%) finished the day higher after pricing its 2.6M share public offering at $20.59 per share, a 3.3% discount to Thursday's close. The company says El.En S.p.A. sold 600Kshares in the offering.

    | Nov. 16, 2012, 4:08 PM
  • Nov. 12, 2012, 12:42 PM

    Cynosure (CYNO -5.6%) is lower today after announcing a 2.6M share secondary offering. El.En. S.p.A. is also offering an additional 600K shares. The company intends to use the net proceeds of its portion of the sale to fund the potential acquisition of targeted products, technologies or businesses. It will not receive any proceeds from the sale of the shares by El.En. S.p.A.

    | Nov. 12, 2012, 12:42 PM | 1 Comment
  • Oct. 23, 2012, 10:51 AM

    Cynosure (CYNO -1%) slips into the red after an early gain of over 10% following its solid Q3 earnings beat this morning. Total revenue soared over 31% Y/Y on strong laser product sales growth in both its U.S. and international markets. Gross margin also improved by 170 bps to 58.2%. The quarter's results are a marked improvement from the same period last year, when it reported a loss of $0.06 per share.

    | Oct. 23, 2012, 10:51 AM
  • Oct. 23, 2012, 8:11 AM
    Cynosure (CYNO): Q3 EPS of $0.25 beats by $0.13. Revenue of $37.1M (+31% Y/Y) beats by $2.5M. Shares +10.6% premarket. (PR)
    | Oct. 23, 2012, 8:11 AM
  • Oct. 2, 2012, 10:22 AM
    Cynosure (CYNO -5%) dips this morning after filing late yesterday to sell 2.94M shares for holders.
    | Oct. 2, 2012, 10:22 AM | 1 Comment
  • Jul. 24, 2012, 8:11 AM
    Cynosure (CYNO): Q2 EPS of $0.20 beats by $0.08. Revenue of $39.6M (+50.2% Y/Y) beats by $3.6M. Shares +11.5% premarket. (PR)
    | Jul. 24, 2012, 8:11 AM
  • Jan. 30, 2012, 12:35 PM

    Cynosure (CYNO +6.7%) jumps after saying its Cellulaze Workstation, a minimally invasive aesthetic device for the treatment of cellulite, has been cleared by the FDA for commercial distribution in U.S. markets. The company is also currently pursing regulatory approval in Canada, the EU, Australia and South Korea.

    | Jan. 30, 2012, 12:35 PM | 1 Comment
Company Description
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States